This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Rajiv De Silva Named President And CEO Of Endo Health Solutions

MALVERN, Pa., Feb. 25, 2013  /PRNewswire/ -- Endo Health Solutions Inc. (Nasdaq: ENDP) today announced that Rajiv De Silva, a pharmaceutical executive who had been President of Valeant Pharmaceuticals and a senior executive at Novartis, has been named Endo's President and Chief Executive Officer, effective March 18.  Mr. De Silva, who will also join the Endo Board of Directors, succeeds David Holveck who is retiring.

"Rajiv is a strong leader with the deep industry experience, outcome-oriented approach, and proven ability to drive results the Board was seeking in our next CEO," said Roger H. Kimmel, Chairman of the Board.  "His track record in generating growth and profitability, managing complex integrations, and delivering for shareholders will serve us well.  We are focused on taking the actions needed to create value for Endo shareholders and believe today's announcement is another key step forward that will enable us to build on Endo's strong foundation.  At the same time, we appreciate Dave Holveck's significant contributions to Endo, including his leadership in reducing the Company's dependence on Lidoderm, and wish him well in his retirement."

Said De Silva, "I am excited to take on the challenge of leading Endo and helping the Company realize its full potential.  Endo occupies a unique position in the healthcare market, able to deliver innovative products and services across multiple platforms with clear strengths in the medically important areas of pain management and urology.  I look forward to working with the Endo team to build on its strengths and deliver top line growth while also improving cost management, execution and integration to enable Endo to make the most of its many opportunities and create value for its shareholders."

Mr. De Silva, 46, has deep experience in the pharmaceutical sector.  He most recently served as President of Valeant Pharmaceuticals, a $20 billion market capitalization specialty pharmaceutical company with a presence in the U.S. and a wide range of international markets.  While at Valeant from 2009 to 2013, Mr. De Silva also served as Chief Operating Officer of Valeant's Specialty Pharmaceuticals business.  During this period, he drove a turnaround plan that resulted in a multi-fold increase in revenues through acquisitions and organic sales growth, substantial improvements in profitability and cash flow generation, and put Valeant among the leading creators of shareholder value in the sector. 

Prior to joining Valeant, Mr. De Silva was a senior executive at Novartis from 2003 to 2008, most recently serving as President of its Vaccines business in the U.S. and the Head of Vaccines in the Americas.  He was previously President and CEO of Novartis Pharmaceuticals Canada and Global Head of Strategic Planning for Novartis Pharma.  Earlier in his career, he was a Principal at McKinsey & Company, where he served as a member of the partnership group that led the global Pharmaceutical and Medical Products practice.

Stock quotes in this article: ENDP 

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,501.65 -12.72 -0.08%
S&P 500 1,875.39 -4.16 -0.22%
NASDAQ 4,126.9670 -34.4910 -0.83%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs